← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchStrongest evidence only (42)Treatment guideline (6)Meta-analysis (5)Phase 3 study (18)Randomized trial (9)Systematic review (4)Clinical trial (601)Review article (228)Early study (phase 1 or 2) (40)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Only studies currently recruiting participants (36)

Filter

Publications and studies (1631)

• Commentary or editorialiAn expert's opinion or commentary, not new research. Genomics reboot for secondary myelofibrosis. (2026/07/02) ♡
• Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia. (2026/07/02) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Splenic Artery Aneurysm Associated with Myelofibrosis Managed by Coil Embolization. (2026/07/01) ♡
• Clinical Characteristics and Survival Outcomes in Patients with Essential Thrombocythemia. (2026/07/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. When Myelofibrosis Clouds the Diagnosis: A Hematopathological Dilemma in an Infant. (2026/07/01) ♡
• Real-world treatment landscape and disease burden of myelofibrosis in Taiwan, South Korea, Japan, and Canada. (2026/07/01) ♡
• CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis. (2026/07/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study. (2026/07/01) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026. (2026/07/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Adult Erythroblastic Sarcoma With PCM1::JAK2 Fusion and a Novel NOP10::NUTM1 Fusion Complicated by Secondary HLH. (2026/07/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Rechallenge of ruxolitinib after momelotinib-related toxicity in a 74-yo woman with secondary myelofibrosis: a case report. (2026/07/01) ♡
• Profile of Philadelphia Chromosome Negative (Ph-) Myeloproliferative Neoplasm with Special Emphasis on Vascular Thrombotic Events and the Response to Cytoreductive Therapy in Polycythemia Vera and Essential Thrombocythemia Patients: A Single Center Study from Kerala. (2026/07/01) ♡
• Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis. (2026/07/01) ♡
• Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison. (2026/06/30) ♡
• TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. (2026/06/30) ♡
• A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications. (2026/06/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Primary hypertrophic osteoarthropathy complicated with myelofibrosis and compound heterozygous SLCO2A1 mutations: a case report and review of literature. (2026/06/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics. (2026/06/29) ♡
• Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms (MPN) and Pruritus. (2026/06/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Unexpected melanoma metastasis with E-cadherin expression in bone marrow. (2026/06/26) ♡
• Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis. (2026/06/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP-SMAD Signaling to Therapeutic Modulation. (2026/06/25) ♡
• Glucose transport dependency defines a therapeutic vulnerability in JAK2V617F-driven myeloproliferative neoplasms. (2026/06/23) ♡
• T-Cell Lymphoma With Sarcoid-Like Reaction and Secondary Myelofibrosis: A Unique Case Report and Literature Review. (2026/06/23) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study. (2026/06/22) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)]. (2026/06/17) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia. (2026/06/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Lysozyme-Associated Nephropathy in Myeloid Neoplasms: A Clinicopathological and Mass Spectrometric Study of Two Cases. (2026/06/16) ♡
• Lived Experience of Patients with Myeloproliferative Neoplasm: An Interpretative Phenomenological Study. (2026/06/16) ♡
• Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. (2026/06/16) ♡
• Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia. (2026/06/15) ♡
• FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features. (2026/06/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Proteomics as a theranostic compass in BCR::ABL1-negative myeloproliferative neoplasms: Integrating biomarker discovery with therapeutic stratification. (2026/06/14) ♡
• Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study. (2026/06/12) ♡
• Coagulation Disorders in Philadelphia Chromosome-negative Myeloproliferative Neoplasms-A Guide for Specialists in Coagulation Disorders. (2026/06/11) ♡
• A model to estimate spleen volume from palpated spleen length in patients with myelofibrosis. (2026/06/10) ♡
• Isolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma. (2026/06/10) ♡
• Exploring the Origin of Cells in the Progression of Primary Myelofibrosis to Acute Myeloid Leukemia Case Report. (2026/06/09) ♡
• Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution. (2026/06/04) ♡
• Application of NanoString Technologies in Chronic Myeloid Leukemia, Essential Thrombocythemia, Primary Myelofibrosis, and Polycythemia Vera: A Pilot Study. (2026/06/03) ♡
• BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms. (2026/06/02) ♡
• Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients. (2026/06/01) ♡
• Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. (2026/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies. (2026/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Splenic Angiosarcoma Misdiagnosed as Primary Myelofibrosis: Report of Two Cases and a Literature Review. (2026/06/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Unmasking Indolent Systemic Mastocytosis in Patients with Unexplained or Treatment-Refractory Osteoporosis: A Case Series with Diagnostic and Therapeutic Implications. (2026/06/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Serial Imaging and Burnout Transition of Extramedullary Hematopoiesis in Sickle Beta-thalassemia: A Two-year Case Study. (2026/06/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis. (2026/05/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates. (2026/05/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treosulfan-Based Conditioning in Allogeneic Stem Cell Transplantation for Myelofibrosis: A Systematic Review. (2026/05/22) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.